GlassScriptPhysician profile
Lydia Stearns
NPI 1174046635
$9,767.78
in general payments reported to CMS, 2019-2025
30 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,525 · 2022: $1,538 · 2023: $2,822 · 2024: $3,698 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,588 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,588.38 |
| Education | $116.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,785.38 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $944.88 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Mycite |
| Axsome Therapeutics, INC. | $816.40 | 2023-2024 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $738.46 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $611.84 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $585.49 | 2021-2024 | Trintellix |
| Corium, LLC | $578.24 | 2022-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $538.17 | 2021-2024 | Invega Sustenna, Spravato |
| Supernus Pharmaceuticals, INC. | $480.62 | 2023-2024 | Qelbree, Qelbree |
| Alkermes, INC. | $423.82 | 2021-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $285.53 | 2021-2024 | Ingrezza |
| Tris Pharma INC | $252.84 | 2022-2024 | Dyanavel Xr |
| Indivior INC. | $198.88 | 2021-2025 | Sublocade |
| Neos Therapeutics, LP | $185.55 | 2021-2024 | Adzenys Xr-Odt |
| Lundbeck LLC | $174.68 | 2021-2024 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $129.27 | 2023-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $126.20 | 2021-2022 | |
| Adlon Therapeutics L.P. | $124.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $123.98 | 2024 | Cobenfy |
| Jazz Pharmaceuticals INC. | $101.15 | 2021-2023 | |
| Eisai INC. | $98.03 | 2021 | |
| Avanir Pharmaceuticals, INC. | $95.84 | 2021-2022 | |
| Bausch Health US, LLC | $82.03 | 2023-2024 | Aplenzin, Wellbutrin |
| Braeburn INC. | $81.71 | 2023-2024 | Brixadi |
| Noven Therapeutics, LLC | $68.19 | 2024 | Xelstrym, Secuado |
| Harmony Biosciences LLC | $59.48 | 2023 | Wakix |
| Vanda Pharmaceuticals INC. | $23.57 | 2024 | Fanapt |
| Uswm, LLC | $21.85 | 2021 | |
| Owp Pharmaceuticals, INC. | $20.36 | 2021 | |
| Vivus LLC | $10.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Stearns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.